Polyplus
Founded Year
2001Stage
Acq - Fin - II | AliveTotal Raised
$3.24MValuation
$0000About Polyplus
Polyplus operates as a biotechnology company. It develops and sells solutions for the delivery of nucleic acids in research, bioproduction, and therapeutics. The company also supplies a wide range of reagents for the transfection of genes, oligonucleotides, and siRNA. It was founded in 2001 and is based in Illkirch-Strasbourg, France. In February 2020, Polyplus was acquired by Warburg Pincus.
Missing: Polyplus's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Polyplus's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Polyplus
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Polyplus is included in 2 Expert Collections, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Polyplus Patents
Polyplus has filed 22 patents.
The 3 most popular patent topics include:
- Battery (electricity)
- Energy storage
- Lithium-ion batteries
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/2/2020 | 9/13/2022 | Computer buses, Fluid dynamics, Thermoplastics, Polymers, Type 1936A-class destroyers | Grant |
Application Date | 10/2/2020 |
|---|---|
Grant Date | 9/13/2022 |
Title | |
Related Topics | Computer buses, Fluid dynamics, Thermoplastics, Polymers, Type 1936A-class destroyers |
Status | Grant |
Latest Polyplus News
Jan 15, 2023
Partager - 6 conseils Très performante, la biotech strasbourgeoise développant des réactifs pour la transfection... La biotech strasbourgeoise développant des réactifs pour la transfection fait l’objet d’un dividend recap initié par ArchiMed, son actionnaire depuis 2016, qui sécurise un niveau de rendement de 4 fois la mise.Les performances de Polyplus Transfection ont amené ArchiMed, son actionnaire depuis 2016 (lire ci-dessous), à procéder à un dividend recap (dette bancaire assortie d’une tranche mezzanine). « Nous n’endettons pas d’emblée les sociétés dans lesquelles nous investissons, rappelle Loïc Kubitza, partner chez Archimed. En revanche, quand elles se développent (...) Cet article est réservé à nos abonnés. 76% reste à lire Pour accéder à cet article, à l'ensemble du site ainsi qu'à nos bases de données, découvrez nos formules d'abonnement .
Polyplus Frequently Asked Questions (FAQ)
When was Polyplus founded?
Polyplus was founded in 2001.
Where is Polyplus's headquarters?
Polyplus's headquarters is located at 850 bd Sebastien Brant, Illkirch-Strasbourg.
What is Polyplus's latest funding round?
Polyplus's latest funding round is Acq - Fin - II.
How much did Polyplus raise?
Polyplus raised a total of $3.24M.
Who are the investors of Polyplus?
Investors of Polyplus include Warburg Pincus, ArchiMed, Sudinnova, CIC Finance, CIC Vizille Capital Innovation and 3 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.